↳ Index > Factsheets > Zopiclone
| Zopiclone | Info |
|---|
| Summary | A nonbenzodiazepine sedative sleep aid (Z-drug), which can have hallucinogenic effects if taken while awake. Often causes users to have a metallic taste in the mouth for ~12h. Has been reported in some cases to cause certain users to black out, redose excessively and undertake dangerous activities such as driving. |
| Dose | Oral Threshold: 3.5mg Light: 3.5-5mg Common: 5-7.5mg Strong: 7.5-15mg Heavy: 15-22.5mg |
| Onset | 15 - 30 minutes (on empty stomach) |
| Duration | 3.5-9 hours |
| Effects | Lethargy, tiredness, a dreamlike state while awake, can induce heavy sleep. |
| Categories | depressant habit-forming common |
| Aliases | imovane zimovane |
| Contraindictions | Liver disease, myasthenia gravis, severe chronic bronchitis, emphysema, sleep apnea, thyroid gland abnormalities, trimipramine, caffeine, alcohol, erythromycin, itraconazole, rifampicin, phenytoin, carbamazepine, ketoconazole, sulfaphenazole, and nefazodone |
| Chemistry | IUPAC: (RS)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate | Formula: C17H17ClN6O3 | Molecular Mass: 388.808 g/mol |
| Pharmacology | GABA-A receptor positive allosteric modulator; Benzodiazepine receptor agonist |
| Pharmacokinetics | Protein Binding: 45 - 80% | Metabolism: various cytochrome P450 liver enzymes | Excretion: respiration (~50%) and urine (7 - 10 %) |
| Legal | Australia: Prescription Only (S4) | United Kingdom: Controlled Drug (POM) | United States: Schedule IV |
| After-effects | 1-12 hours. |